Get the Stockscreener App
2.37
5.80%
0.13
After Hours:
2.35
-0.02
-0.84%
Inflarx N V Stock (IFRX) Latest News
InflaRx (IFRX) Stock Sees After-Market Gains - Stocks Telegraph
InflaRx Announces Participation in Guggenheim SMID Cap Biotech Conference - GlobeNewswire
InflaRx to Present at Guggenheim SMID Cap Biotech Conference: Spotlight on Vilobelimab Pipeline - StockTitan
Short Interest in InflaRx (NASDAQ:IFRX) Rises By 15.0% - MarketBeat
InflaRx Stock Rises 8% on Conditional EC Nod for COVID-19 Drug - MSN
InflaRx (NASDAQ:IFRX) Earns Buy Rating from HC Wainwright - Defense World
InflaRx stock reiterated at Buy at H.C. Wainwright after EU drug approval - MSN
InflaRx secures European Commission approval for ARDS drug - European Biotechnology News
InflaRx (NASDAQ:IFRX) Given Buy Rating at HC Wainwright - MarketBeat
InflaRx wins EU approval for Gohibic in Covid-19-induced ARDS - Yahoo Finance
InflaRx Secures EU Approval for GOHIBIC in Treating COVID-19-Induced ARDS - TipRanks
InflaRx Receives European Commission Approval for GOHIBIC® - GlobeNewswire
InflaRx gets EU okay for Gohibic for COVID-19 respiratory distress - Seeking Alpha
InflaRx's GOHIBIC Makes History as First EU-Approved Treatment for COVID-19 ARDS - StockTitan
InflaRx Announces Participation in January Events in San Francisco - The Manila Times
InflaRx to Present at Major Biotech Events in San Francisco, Showcasing Novel Disease Response Solutions - StockTitan
InflaRx (NASDAQ:IFRX) Sees Large Growth in Short Interest - MarketBeat
InflaRx N.V. (IFRX) Reports Q3 Loss, Tops Revenue Estimates - MSN
US Penny Stocks To Watch In December 2024 - Simply Wall St
Analyst highlights long-term sales growth potential for Inflarx shares with INF904 therapy - Investing.com Nigeria
Analyst highlights long-term sales growth potential for Inflarx shares with INF904 therapy By Investing.com - Investing.com South Africa
InflaRx Advances INF904 for CSU and HS with Phase 2a Study - Dermatology Times
InflaRx (NASDAQ:IFRX) Given "Buy" Rating at HC Wainwright - MarketBeat
InflaRx Begins Phase 2a Trial for Innovative Anti-Inflammatory Drug - TipRanks
InflaRx Announces First Patient Dosed in Phase 2a Study for Oral C5aR Inhibitor INF904 - GlobeNewswire
InflaRx Launches Phase 2a Trial for Billion-Dollar Skin Disease Drug INF904 - StockTitan
InflaRx (NASDAQ:IFRX) Trading 3.8% HigherHere's Why - MarketBeat
InflaRx N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Lucid Capital sets Inflarx NV Buy stock rating on clinical trial potential - Investing.com Canada
10 Best German Stocks To Buy Now - Insider Monkey
Is InflaRx N.V. (IFRX) the Best German Stock to Buy Now? - Insider Monkey
InflaRx receives positive CHMP opinion for SARS-CoV-2-induced acute respiratory distress treatment - MSN
InflaRx's GOHIBIC gets EMA panel nod for COVID-19 ARDS By Investing.com - Investing.com Canada
InflaRx's GOHIBIC gets EMA panel nod for COVID-19 ARDS - Investing.com India
InflaRx’s GOHIBIC gets EMA panel nod for COVID-19 ARDS By Investing.com - ழ தொலைக்காட்சி
InflaRx Receives Positive CHMP Opinion for GOHIBIC® - GlobeNewswire
InflaRx's GOHIBIC Secures Key EU Backing for COVID ARDS Treatment After 24% Mortality Reduction | IFRX Stock News - StockTitan
FY2024 EPS Estimates for InflaRx Cut by Leerink Partnrs - Defense World
U.S. Stock market top gainers: Omeros Corporation gains 52.99% while InflaRx N.V surges by 40.94% - Business Upturn
FY2024 Earnings Forecast for InflaRx Issued By HC Wainwright - MarketBeat
FY2024 EPS Estimates for InflaRx Reduced by Leerink Partnrs - MarketBeat
Prenetics Global And 2 Other US Penny Stocks To Watch - Simply Wall St
InflaRx Reports Q3 2024 Financial Results and Progress - Yahoo Finance
5.49%
0.79%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):